MyMD Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.38 Insider Own0.60% Shs Outstand39.05M Perf Week13.16%
Market Cap72.31M Forward P/E- EPS next Y- Insider Trans4.13% Shs Float33.85M Perf Month-8.51%
Income-14.70M PEG- EPS next Q- Inst Own10.70% Short Float / Ratio6.10% / 4.69 Perf Quarter49.57%
Sales- P/S- EPS this Y75.20% Inst Trans-16.73% Short Interest2.06M Perf Half Y-32.28%
Book/sh0.47 P/B3.66 EPS next Y- ROA-68.00% Target Price- Perf Year-61.17%
Cash/sh0.17 P/C10.18 EPS next 5Y- ROE-76.20% 52W Range0.90 - 6.15 Perf YTD49.57%
Dividend- P/FCF- EPS past 5Y67.40% ROI- 52W High-72.03% Beta2.23
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low91.11% ATR0.21
Employees9 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)46.71 Volatility11.05% 12.03%
OptionableYes Debt/Eq0.00 EPS Q/Q34.90% Profit Margin- Rel Volume1.29 Prev Close1.70
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume439.67K Price1.72
Recom- SMA20-7.10% SMA50-12.07% SMA200-32.08% Volume566,745 Change1.18%
Mar-20-23 08:55AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
Feb-21-23 08:45AM
09:40AM Loading…
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
Jun-21-22 10:30AM
09:15AM Loading…
Apr-05-22 09:15AM
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
10:30AM Loading…
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rivard PaulEVP of Operations, GCDec 08Buy1.5310,00015,300225,000Dec 08 08:24 PM